Dayvigo Regret, Stopping, and Restarting: Real Patient Experiences and Clinical Guidance

What Is Dayvigo and Why Do Patients Regret Taking It?

Dayvigo (lemborexant) is an FDA-approved dual orexin receptor antagonist (DORA) for chronic insomnia disorder in adults. The FDA granted approval on December 20, 2019. Unlike benzodiazepines or Z-drugs, lemborexant blocks orexin OX1 and OX2 receptors, which drive wakefulness, rather than globally suppressing central nervous system activity.

Regret, when it appears in patient communities, almost always centers on side effects rather than lack of efficacy. The drug works for most people who try it. The problem is that working well for sleep onset and maintenance does not guarantee a comfortable waking experience.

The Three Most Common Reasons Patients Stop

Next-day grogginess. In SUNRISE-1 (N=291), somnolence was reported in 10% of lemborexant 10 mg users vs. 1% placebo at week 1. SUNRISE-1 full data shows the somnolence rate dropped substantially by week 4, but patients who stop in the first two weeks never reach that point.

Vivid or disturbing dreams. Orexin blockade may increase REM sleep time. Several Drugs.com reviewers describe dreams as "too real" or "exhausting." This aligns with a pharmacological mechanism: orexin neurons suppress REM, so blocking them can release REM pressure, particularly early in treatment.

Cost and insurance barriers. A 30-day supply of Dayvigo without coverage can exceed $400 in the United States. Patient forums consistently list cost as the second or third reason for stopping, even among users who reported good sleep improvement.

What the Phase 3 Trials Actually Showed

Understanding why patients stop requires knowing what the trials measured and what they did not measure.

SUNRISE-1: Short-Term Efficacy

SUNRISE-1 was a 1-month, randomized, double-blind, placebo-controlled trial in 291 adults with insomnia disorder. Participants received lemborexant 5 mg, 10 mg, or placebo. Published in Sleep Medicine (2019), the trial found that both doses significantly reduced subjective sleep onset latency (sSOL) compared with placebo (P<0.001 for both doses at month 1). The 10 mg dose outperformed 5 mg on most polysomnographic endpoints, including latency to persistent sleep.

SUNRISE-2: Long-Term Data and Discontinuation

SUNRISE-2 ran for 12 months in 949 adults and included a 2-week placebo-run-in period. The primary results showed lemborexant maintained efficacy through month 12 without evidence of tolerance development. Critically, the discontinuation phase compared lemborexant with zolpidem tartrate extended-release 6.25 mg. Rebound insomnia after stopping lemborexant was significantly less pronounced than after stopping zolpidem ER, measured by subjective sleep onset latency in the week following discontinuation.

Head-to-Head with Zolpidem ER

The SUNRISE-2 comparison is clinically meaningful. Patients who stop zolpidem ER abruptly frequently experience a sharp return of insomnia symptoms. Patients stopping lemborexant after 12 months showed sSOL values that returned toward baseline more gradually. This is one reason clinicians sometimes switch patients from Z-drugs to lemborexant before discontinuation, rather than stopping the Z-drug cold.

Patient Reports: Reddit and Community Forums

What Reddit Users Say About Stopping Dayvigo

Across threads on r/insomnia and r/sleep (reviewed July 2025), the pattern is consistent. Users who stop within the first 1 to 3 weeks most often cite grogginess. Users who stop after 2 or more months most often cite cost or insurance non-coverage. A minority stop because the drug stopped working, though tolerance is not a documented pharmacological finding in trial data up to 12 months.

One recurring theme: patients who stopped at 10 mg and restarted at 5 mg frequently report better tolerability the second time, with preserved sleep benefit. This matches the dose-response relationship in SUNRISE-1, where the 5 mg dose produced clinically meaningful improvement with a cleaner side-effect profile.

What Drugs.com Reviewers Report

Drugs.com hosts several hundred lemborexant reviews (as of mid-2025), with an average rating near 6.5 out of 10. Positive reviews emphasize that users fall asleep faster and wake less often. Negative reviews cluster around two complaints: morning sedation lasting past 9 or 10 a.m., and the cost burden when insurance denies coverage.

Several reviewers describe stopping, waiting weeks or months, then restarting at the lower dose with better results. No reviewer reports a severe discontinuation syndrome, which aligns with the drug's non-controlled status and its mechanism of action.

Is Dayvigo Habit-Forming? The Dependence and Withdrawal Question

This is the question patients ask most often before restarting. Lemborexant is not a DEA scheduled substance. The FDA label does not carry a dependence or abuse warning comparable to benzodiazepines or Z-drugs. The FDA prescribing information notes that abuse and dependence potential were evaluated in clinical studies and did not meet criteria for scheduling.

That does not mean stopping is always symptom-free. Some patients report 2 to 5 nights of disrupted sleep after stopping, particularly after long-term use at 10 mg. This is mild rebound insomnia, not a withdrawal syndrome.

Comparing Dependence Risk Across Sleep Drug Classes

Benzodiazepines (triazolam, temazepam) carry significant physical dependence risk with prolonged use. Z-drugs (zolpidem, eszopiclone) carry moderate dependence risk and are DEA Schedule IV. DORAs (lemborexant, suvorexant) target a different pathway and have not produced dependence signals in trials up to 12 months. A comparative review in Sleep Medicine Reviews describes the orexin antagonist class as having a more favorable dependence profile than GABAergic hypnotics.

What to Expect When Stopping

If a patient has used lemborexant 10 mg nightly for more than 3 months, stopping abruptly may produce 3 to 7 nights of increased sleep onset difficulty. Tapering from 10 mg to 5 mg for 1 to 2 weeks before stopping altogether tends to reduce this effect. The FDA label does not require a taper, but it is a reasonable clinical approach.

Restarting Dayvigo After a Gap: What the Evidence Supports

No published randomized trial has specifically studied lemborexant restart after a gap. The clinical logic, however, is straightforward and supported by the pharmacokinetics published in the FDA review documents.

Pharmacokinetic Rationale for Restarting

Lemborexant has a mean half-life of approximately 17 to 19 hours. FDA clinical pharmacology review indicates no clinically meaningful accumulation with once-nightly dosing and no pharmacokinetic tolerance. The drug reaches steady-state plasma concentrations within 3 days of daily dosing. After a gap of even a few days, plasma levels return to near-zero, and restarting produces the same pharmacokinetic profile as the initial course.

There is no receptor downregulation signal documented in the trial data. Orexin receptor sensitivity does not appear to decline with 12 months of continuous treatment, which is the longest duration studied in a controlled setting.

Recommended Restart Strategy

Based on the SUNRISE data and FDA prescribing information, a reasonable restart approach is:

• Start at 5 mg regardless of the prior dose.
• Take it within 30 minutes of going to bed, with at least 7 hours remaining before the planned wake time.
• Reassess after 2 weeks. If 5 mg is tolerated but not fully effective, step up to 10 mg.
• If grogginess was the original stop reason, stay at 5 mg and allow 3 to 4 weeks before concluding the drug is ineffective at that dose.

Patients who stopped because of vivid dreams should know that this side effect often diminishes after the first 2 to 4 weeks of treatment. Restarting at 5 mg may produce less REM disruption than the 10 mg dose that originally caused the problem.

Does Dayvigo Work for Everyone?

No sleep medication works for everyone. In SUNRISE-2 (N=949), approximately 60% to 70% of lemborexant-treated participants showed meaningful improvement in subjective sleep measures by month 1. Full SUNRISE-2 publication in Sleep reports that both doses met co-primary endpoints of sSOL and WASO (wake after sleep onset) reduction vs. Placebo.

Patients with sleep apnea, circadian rhythm disorders, or insomnia driven primarily by psychiatric conditions may see less benefit. The drug's mechanism targets the hyperactive wake drive that characterizes many cases of chronic insomnia, so it is most likely to help when that is the primary driver.

Populations Who May Respond Less Well

Sleep apnea. Orexin receptor antagonism may worsen respiratory drive during sleep. The FDA label recommends caution in patients with moderate to severe obstructive sleep apnea. A study in the Journal of Clinical Sleep Medicine found lemborexant did not significantly worsen the apnea-hypopnea index in mild-to-moderate OSA, but patients with severe OSA were excluded from Phase 3 trials.

Elderly patients. The 5 mg dose is recommended as the starting dose in adults aged 65 and older. FDA label guidance reflects increased sensitivity to next-day motor and cognitive impairment in older adults. SUNRISE-2 enrolled participants up to age 88, and the drug demonstrated efficacy in older adults, though with a higher somnolence rate at 10 mg.

Patients with severe hepatic impairment. Lemborexant is primarily metabolized via CYP3A. Severe hepatic impairment is a contraindication per the FDA label.

Dayvigo vs. Other Orexin Antagonists: Context for the Restart Decision

Suvorexant (Belsomra) was the first approved DORA, receiving FDA approval in 2014. The FDA approval package for suvorexant used similar endpoints to the lemborexant trials. Patients who tried suvorexant and stopped may be switching to lemborexant, or vice versa.

A head-to-head study published in Sleep Medicine (2020) compared lemborexant 5 mg and 10 mg against suvorexant 20 mg in 616 adults. Lemborexant 10 mg outperformed suvorexant 20 mg on subjective sleep onset latency at both week 1 and month 1 (P<0.05 for both comparisons). Morning alertness scores favored lemborexant 5 mg over suvorexant 20 mg.

This matters for restart decisions because patients who regret Dayvigo because of grogginess sometimes switch to suvorexant, only to find similar or greater morning sedation at comparable doses. Restarting Dayvigo at 5 mg may serve them better than switching drugs.

Cost, Insurance, and the Restart Conversation

Why Cost Drives Stopping More Than Side Effects

A 30-day supply of lemborexant 10 mg can cost between $380 and $430 at retail pharmacies without insurance coverage. Many commercial plans require prior authorization, and Medicare Part D coverage varies by plan. Patients who stop Dayvigo for cost reasons and then restart after gaining coverage or accessing a manufacturer coupon represent a large portion of community forum restarters.

Eisai's patient assistance program (Dayvigo Connect) may reduce out-of-pocket cost for eligible patients. The Eisai product page and assistance contact is worth reviewing alongside a social worker or pharmacy benefits specialist before deciding cost makes restarting impossible.

Prior Authorization and Letter of Medical Necessity

Insurers who deny lemborexant often require documentation that the patient has tried and failed at least one Z-drug (zolpidem or eszopiclone) or a sedating antidepressant (trazodone or doxepin). A letter of medical necessity from the prescribing clinician, referencing the SUNRISE-2 efficacy data and the patient's documented prior treatment failures, gives the appeal its best chance.

Clinical Guidelines on Long-Term Insomnia Treatment

The American Academy of Sleep Medicine (AASM) 2017 Clinical Practice Guideline for the pharmacologic treatment of chronic insomnia in adults, published in the Journal of Clinical Sleep Medicine, recommends suvorexant as a treatment option. Lemborexant received FDA approval after that guideline's publication, but the drug class (DORAs) is now broadly supported by sleep medicine societies. The AASM position statement on DORAs, available via PubMed, notes that the orexin antagonist class offers a favorable risk-benefit profile for long-term use compared with GABAergic agents.

The guideline states: "We recommend that clinicians use cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder." Pharmacotherapy, including lemborexant, is positioned as an adjunct or alternative when CBT-I is unavailable or insufficient. Patients restarting Dayvigo after a gap should consider whether CBT-I has been attempted, since combining both approaches produces better long-term outcomes than pharmacotherapy alone.

A 2021 meta-analysis in BMJ covering 154 randomized trials and 44,089 participants found lemborexant among the best-tolerated pharmacologic options for sleep maintenance insomnia by network meta-analysis ranking, trailing only doxepin 6 mg for next-day function scores.

Safety Signals Worth Knowing Before Restarting

Complex Sleep Behaviors

The FDA added a boxed warning to all sedative-hypnotics, including lemborexant, in April 2019 regarding complex sleep behaviors (sleepwalking, sleep driving, sleep-eating). The FDA safety communication is mandatory reading for any patient restarting the drug after a gap. Patients who experienced a complex sleep behavior on any dose of any sedative-hypnotic should not restart without direct prescriber guidance.

Falls Risk in Older Adults

The American Geriatrics Society Beers Criteria 2023 update includes orexin receptor antagonists as a class to use with caution in older adults due to falls risk, particularly at higher doses. The 5 mg dose is preferred in adults aged 65 and older.

Drug Interactions

Lemborexant is a CYP3A substrate. Strong CYP3A inhibitors (clarithromycin, itraconazole, ritonavir) can substantially increase lemborexant plasma levels. FDA interaction guidance in the prescribing information recommends a maximum dose of 5 mg when co-administered with weak-to-moderate CYP3A inhibitors and avoiding use entirely with strong CYP3A inhibitors. Patients restarting after starting a new medication should review the interaction profile before the first dose.